Written by Julia Rostova
UnitedHealth delivered the kind of quarter that reminds investors why scale in managed care and health services can still function as a moat. The company reported second-quarter 2026 revenues of $112.0 billion, earnings from operations of $8.0 billion, earnings of $6.04 per share, and adjusted earnings of $6.38 per share. Just as importantly, management raised full-year 2026 guidance to an EPS range of $18.45 to $18.95 and an adjusted EPS range of $19.50 to $20.00. After periods when investors worried more intensely about cost trends, reimbursement pressure, and healthcare-policy noise, this quarter suggests the franchise has regained a meaningful degree of earnings clarity.
That is the business case. The investment case is more complicated. UnitedHealth is no longer trading like a wounded healthcare giant. On Finviz, the stock sits at $426.09 against a consensus target price of $477.80, implying roughly 12.1% upside. That is respectable, but not so large that investors can ignore valuation discipline after a strong rebound. The shares trade at 27.40x earnings, 19.21x forward earnings, 0.86x sales, and 3.95x book. Those multiples are not absurd for a business of this quality, but they do imply the market has already recognized a large part of the recovery.
My verdict on UNH is HOLD with a $475 price target. The franchise deserves respect and probably patience, but the obvious bargain phase looks over.
| Stock | Current price | Verdict | Price target |
| UNH | $426.09 | HOLD | $475 |
| ELV | $373.11 | BUY | $445 |
| CI | $281.45 | BUY | $340 |
The bull case for UnitedHealth remains powerful because the company’s structure is still unusually hard to replicate. UnitedHealthcare and Optum create a broad integrated platform spanning insurance, care delivery, pharmacy, services, and data-heavy healthcare operations. That structure can produce advantages in pricing intelligence, cost management, provider relationships, and cross-segment resilience that simpler insurers often cannot match. When the company is executing well enough to raise guidance, investors are reminded that scale here is not just size. It is coordination capacity.
That said, the market is paying for that quality again. UNH’s 29.1% year-to-date stock performance and 47.9% one-year performance suggest that a meaningful rerating is already underway. In that context, upside becomes less about discovering a misunderstood franchise and more about judging whether the earnings recovery can keep compounding fast enough to justify the multiple. That is possible, but it is no longer easy money.
Elevance Health offers a more interesting pure valuation case. The shares trade at $373.11 against a $445.57 target price, implying about 19.4% upside. ELV trades at 16.58x earnings, 12.62x forward earnings, 0.40x sales, and 1.80x book, all meaningfully cheaper than UnitedHealth. The business is not as broad or as symbolically dominant, but the valuation discount is real. My verdict on ELV is BUY with a $445 price target. It offers a better balance between business quality and available upside than UNH at today’s levels.
Cigna is the most statistically attractive of the three. The stock trades at $281.45 versus a $340.65 target price, implying roughly 21.0% upside. It also carries the cheapest multiple stack in the group, with a 11.92x P/E, 8.41x forward P/E, 0.27x sales, and 1.77x book. Cigna is not the same kind of integrated healthcare franchise as UnitedHealth, but it does not need to be to produce strong stock returns from here. It only needs the market to stop valuing it as cautiously as it does now. My verdict on CI is BUY with a $340 price target.
| Company | P/E | Forward P/E | P/S | P/B | Oper. Margin | Profit Margin | Implied upside to consensus target | Reading |
| UnitedHealth | 27.40x | 19.21x | 0.86x | 3.95x | 4.82% | 3.14% | 12.1% | Highest-quality franchise, but much of the recovery is now priced in |
| Elevance | 16.58x | 12.62x | 0.40x | 1.80x | 3.63% | 2.47% | 19.4% | Good business at a more forgiving valuation |
| Cigna | 11.92x | 8.41x | 0.27x | 1.77x | 3.85% | 2.26% | 21.0% | Cheapest setup with the clearest rerating room |
The risk to the UnitedHealth thesis is not hard to identify. Healthcare is still a politically exposed, cost-sensitive sector, and even a company this large cannot fully insulate itself from utilization surprises, reimbursement pressure, or sentiment swings when policy narratives heat up. A premium-quality business can still deliver mediocre stock returns if expectations recover faster than fundamentals improve.
This is where the capacity-to-suffer framework matters. UnitedHealth still looks like the kind of business that can deserve patience because the core franchise is not broken and the integrated model remains strategically strong. But patience should not be confused with aggressiveness. My conclusion is that UNH is a HOLD at $475: excellent, resilient, and worthy of ownership, but no longer cheap. Elevance is a BUY at $445 because the valuation leaves more room for appreciation. Cigna is also a BUY at $340 because the discount is deeper still. UnitedHealth has regained earnings clarity. The stock has already regained a large share of the market’s confidence as well.
*This article is for informational and educational purposes only and is not financial advice. Investors should do their own due diligence, consider their risk tolerance, and remember that past performance does not guarantee future results.*
